Travis Salzillo1, Vimbai Mawoneke2, Joseph Weygand2, Akaanksh Shetty2, Joy Gumin3, Niki Zacharias2, Seth Gammon2, David Piwnica-Worms2, Gregory Fuller4, Christopher Logothetis5, Frederick Lang3, and Pratip Bhattacharya2
1Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 4Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 5Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
1Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 4Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 5Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
During tumor regression and recurrence, hyperpolarized MR detected significant
changes in pyruvate-to-lactate conversion. In contrast, tumor volume
measurements were not significantly altered. nLac can serve as a biomarker to
predict long-term response shortly after radiotherapy.
In vivo pyruvate-to-lactate
conversion is significantly altered throughout tumor development, regression,
and recurrence. Individual nLac values, measured with hyperpolarized 13C
MRS, are plotted as a function of time for control mice (red circles) and
untreated tumor-bearing mice (blue squares) during tumor development (A). Individual nLac values are plotted for treated tumor-bearing mice (green triangles) during
tumor regression and recurrence (B).
Individual nLac values are plotted across the entirety of
tumor progression (C). *p < 0.05, **p <
0.01, ***p < 0.001.
Percent change of nLac, but not tumor volume, is significantly altered
during tumor regression and recurrence. Repeated measures of tumor volume are
acquired over time in treated mice with anatomic MRI (A) and hyperpolarized MRS (B).
At each time-point, volume and nLac were normalized to their initial value
following treatment and plotted as percent change over time (C). *p < 0.05, ***p < 0.001.
